Details of the Drug

General Information of Drug (ID: DMUTEX3)

Drug Name

Amiodarone

Synonyms

Amidorone; Aminodarone; Amiobeta; Amiodarex; Amiodarona; Amiodarons; Amiodaronum; Amiohexal; Amjodaronum; Ancar; Aratac;Arycor; Braxan; Corbionax; Cordarex; Cordarone; Kordaron; Labaz; Ortacrone; Pacerone; Rytmarone; Sedacoron; Sedacorone; Tachydaron; ASTA Medica Brand of Amiodarone Hydrochloride; Alphapharm Brand of Amiodarone Hydrochloride; Amiodarone Base; Armstrong Brand of Amiodarone Hydrochloride; Berenguer Infale Brand of Amiodarone Hydrochloride; Betapharm Brand of Amiodarone Hydrochloride; Cordarone Intravenous; G Gam Brand of Amiodarone Hydrochloride; Hexal Brand of Amiodarone Hydrochloride; Leurquin Brand of Amiodarone Hydrochloride; Pharma Investi Brand of Amiodarone Hydrochloride; Sanofi Winthrop Brand of Amiodarone Hydrochloride; Wyeth Brand of Amiodarone Hydrochloride; Ethylaminoethoxy)benzoyl]benzofuran; L 3428; L3428; SKF 33134A; Amio-Aqueous IV; Amiodarona [INN-Spanish]; Amiodaronum [INN-Latin]; Aratac (TN); Arycor (TN); Atlansil (TN); Cordarone (TN); L-3428; Pacerone (TN); Pms-Amiodarone; SKF 33134-A; Amiodarone (USAN/INN); Amiodarone [USAN:BAN:INN]; Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl; Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI); (2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone; (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone; (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone; (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone; (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone; (2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine; 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran; 2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran; 2-Butyl-3-[3,5-diiodo-4-(2-di; 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone; 2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone; 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran

Indication

Disease Entry	ICD 11	Status	REF
Tachyarrhythmias	BC71	Approved	[1]
Ventricular tachycardia	BC71	Approved	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2/3	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Antiarrhythmic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 3

Molecular Weight (mw)

645.3

Logarithm of the Partition Coefficient (xlogp)

7.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.9 mL/min/kg [5]
Elimination: 0% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 820 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 41.37459 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.0002% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 60 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.7 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Sudden cardiac death	Not Available	KCNQ1	OT8SPJNX	[7]
Sudden cardiac death	Not Available	KCNE1	OTZNQUW9	[7]
-----------

Chemical Identifiers

Formula: C25H29I2NO3
IUPAC Name: (2-butyl-1-benzofuran-3-yl)-[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone
Canonical SMILES: CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
InChI: InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
InChIKey: IYIKLHRQXLHMJQ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2157
ChEBI ID: CHEBI:2663
CAS Number: 1951-25-3
DrugBank ID: DB01118
TTD ID: D0L5WM
VARIDT ID: DR00642
INTEDE ID: DR0093
ACDINA ID: D00031

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Modulator	[8]
HUMAN two pore channel subtype 2 (TPC2)	TTHQJ2Y	TPC2_HUMAN	Blocker	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[12]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[13]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[14]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[14]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[15]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[16]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP)	OTB8HCED	CN37_HUMAN	Gene/Protein Processing	[17]
26S proteasome non-ATPase regulatory subunit 11 (PSMD11)	OT8KO67V	PSD11_HUMAN	Gene/Protein Processing	[17]
3',5'-cyclic-AMP phosphodiesterase 7B (PDE7B)	OTK3SHT2	PDE7B_HUMAN	Gene/Protein Processing	[17]
3-oxoacyl- synthase, mitochondrial (OXSM)	OTMDWHOM	OXSM_HUMAN	Gene/Protein Processing	[17]
5'(3')-deoxyribonucleotidase, mitochondrial (NT5M)	OTJF73BA	NT5M_HUMAN	Gene/Protein Processing	[17]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1)	OT7TNF0L	AAPK1_HUMAN	Post-Translational Modifications	[18]
5'-AMP-activated protein kinase catalytic subunit alpha-2 (PRKAA2)	OTU1KZPV	AAPK2_HUMAN	Post-Translational Modifications	[18]
5-aminolevulinate synthase, non-specific, mitochondrial (ALAS1)	OTQY6ZSF	HEM1_HUMAN	Gene/Protein Processing	[17]
Acetyl-CoA carboxylase 1 (ACACA)	OT5CQPZY	ACACA_HUMAN	Gene/Protein Processing	[17]
Acid ceramidase (ASAH1)	OT1DNGXL	ASAH1_HUMAN	Gene/Protein Processing	[19]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Amiodarone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Propafenone.	Ventricular tachyarrhythmia [BC71]	[20]
Flecainide	DMSQDLE	Major	Decreased metabolism of Amiodarone caused by Flecainide mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[21]
-----------

Coadministration of a Drug Treating the Disease Different from Amiodarone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Amiodarone and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[22]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Ivosidenib.	Acute myeloid leukaemia [2A60]	[23]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Midostaurin.	Acute myeloid leukaemia [2A60]	[23]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Idarubicin.	Acute myeloid leukaemia [2A60]	[23]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Arn-509.	Acute myeloid leukaemia [2A60]	[23]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Gilteritinib.	Acute myeloid leukaemia [2A60]	[23]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Oliceridine.	Acute pain [MG31]	[23]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Amiodarone due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[24]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Amiodarone due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[24]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Ivabradine.	Angina pectoris [BA40]	[24]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Dronedarone.	Angina pectoris [BA40]	[23]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[23]
Cilostazol	DMZMSCT	Moderate	Decreased metabolism of Amiodarone caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[23]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Amiodarone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[25]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Levalbuterol.	Asthma [CA23]	[26]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Amiodarone and Pirbuterol.	Asthma [CA23]	[27]
Budesonide	DMJIBAW	Moderate	Decreased metabolism of Amiodarone caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[28]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Amiodarone caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[29]
Roflumilast	DMPGHY8	Moderate	Decreased metabolism of Amiodarone caused by Roflumilast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[24]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[23]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[23]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Amiodarone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Levofloxacin	DMS60RB	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Troleandomycin	DMUZNIG	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Troleandomycin.	Bacterial infection [1A00-1C4Z]	[32]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Retigabine.	Behcet disease [4A62]	[23]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Amiodarone caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[24]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Amiodarone and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[33]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Eribulin.	Breast cancer [2C60-2C6Y]	[23]
Talazoparib	DM1KS78	Major	Decreased clearance of Amiodarone due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[24]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Lapatinib.	Breast cancer [2C60-2C6Y]	[23]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Amiodarone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Amiodarone caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Bosutinib.	Breast cancer [2C60-2C6Y]	[23]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Amiodarone caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[36]
Iodipamide	DMXIQYS	Moderate	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Iodipamide.	Cholelithiasis [DC11]	[37]
Corticotropin	DMP9TWZ	Major	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Corticotropin.	Chronic kidney disease [GB61]	[38]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Amiodarone and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[23]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Amiodarone and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[26]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Amiodarone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Anisindione	DM2C48U	Major	Decreased metabolism of Amiodarone caused by Anisindione mediated inhibition of CYP450 enzyme.	Coagulation defect [3B10]	[39]
Panitumumab	DMQPD1F	Major	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Panitumumab.	Colorectal cancer [2B91]	[38]
Intedanib	DMSTA36	Moderate	Decreased clearance of Amiodarone due to the transporter inhibition by Intedanib.	Colorectal cancer [2B91]	[40]
Ulipristal	DMBNI20	Minor	Decreased metabolism of Amiodarone caused by Ulipristal mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[24]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Halothane.	Corneal disease [9A76-9A78]	[23]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Sevoflurane.	Corneal disease [9A76-9A78]	[23]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Probucol.	Coronary atherosclerosis [BA80]	[23]
Oxtriphylline	DMLHSE3	Moderate	Decreased metabolism of Amiodarone caused by Oxtriphylline mediated inhibition of CYP450 enzyme.	Cough [MD12]	[29]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Pasireotide.	Cushing syndrome [5A70]	[23]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Osilodrostat.	Cushing syndrome [5A70]	[23]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Amiodarone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[41]
Rivaroxaban	DMQMBZ1	Moderate	Decreased metabolism of Amiodarone caused by Rivaroxaban mediated inhibition of CYP450 enzyme.	Deep vein thrombosis [BD71]	[42]
Vilazodone	DM4LECQ	Moderate	Decreased metabolism of Amiodarone caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[43]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Amiodarone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[44]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Escitalopram.	Depression [6A70-6A7Z]	[23]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Clomipramine.	Depression [6A70-6A7Z]	[23]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Doxepin.	Depression [6A70-6A7Z]	[23]
Ospemifene	DMC4GEI	Moderate	Decreased metabolism of Amiodarone caused by Ospemifene mediated inhibition of CYP450 enzyme.	Dyspareunia [GA12]	[45]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Deutetrabenazine.	Dystonic disorder [8A02]	[23]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Ingrezza.	Dystonic disorder [8A02]	[23]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Amiodarone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[46]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Amiodarone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Brivaracetam	DMSEPK8	Minor	Decreased metabolism of Amiodarone caused by Brivaracetam mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Amiodarone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Amiodarone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[47]
Eslicarbazepine	DMZREFQ	Major	Increased metabolism of Amiodarone caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[47]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Amiodarone and Cannabidiol.	Epileptic encephalopathy [8A62]	[24]
Nadolol	DMW6GVL	Moderate	Increased risk of atrioventricular block by the combination of Amiodarone and Nadolol.	Essential hypertension [BA00]	[48]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Amiodarone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[49]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Solifenacin.	Functional bladder disorder [GC50]	[23]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Amiodarone caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[50]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Amiodarone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[25]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Amiodarone caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[22]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[23]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Amiodarone caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[24]
Dichlorphenamide	DMH7IDQ	Major	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Dichlorphenamide.	Glaucoma [9C61]	[38]
Metipranolol	DMJMVKI	Moderate	Increased risk of atrioventricular block by the combination of Amiodarone and Metipranolol.	Glaucoma [9C61]	[48]
Levobunolol	DMTNFCQ	Moderate	Increased risk of bradycardia by the combination of Amiodarone and Levobunolol.	Glaucoma [9C61]	[48]
Carvedilol	DMHTEAO	Moderate	Increased risk of bradycardia by the combination of Amiodarone and Carvedilol.	Heart failure [BD10-BD1Z]	[48]
Digitoxin	DMWVIGP	Major	Increased plasma concentration of Amiodarone and Digitoxin due to competitive binding of plasma proteins.	Heart failure [BD10-BD1Z]	[51]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Amiodarone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[52]
Simeprevir	DMLUA9D	Moderate	Decreased metabolism of Amiodarone caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[53]
Telaprevir	DMMRV29	Major	Decreased metabolism of Amiodarone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[24]
Rifapentine	DMCHV4I	Major	Increased metabolism of Amiodarone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[47]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Amiodarone due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[54]
MK-1439	DM215WE	Minor	Decreased metabolism of Amiodarone caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Amiodarone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Amiodarone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Amiodarone caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Amiodarone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Amiodarone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[59]
Maraviroc	DMTL94F	Moderate	Decreased clearance of Amiodarone due to the transporter inhibition by Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[60]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Amiodarone and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[61]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Amiodarone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[23]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Amiodarone caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[62]
Acebutolol	DM0TI4U	Moderate	Increased risk of bradycardia by the combination of Amiodarone and Acebutolol.	Hypertension [BA00-BA04]	[48]
Aliskiren	DM1BV7W	Moderate	Decreased clearance of Amiodarone due to the transporter inhibition by Aliskiren.	Hypertension [BA00-BA04]	[23]
Penbutolol	DM4ES8F	Moderate	Increased risk of atrioventricular block by the combination of Amiodarone and Penbutolol.	Hypertension [BA00-BA04]	[48]
Nebivolol	DM7F1PA	Moderate	Increased risk of bradycardia by the combination of Amiodarone and Nebivolol.	Hypertension [BA00-BA04]	[48]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Amiodarone due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[63]
Pirfenidone	DM6VZFQ	Major	Decreased metabolism of Amiodarone caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[22]
Retapamulin	DM9JXB7	Minor	Decreased metabolism of Amiodarone caused by Retapamulin mediated inhibition of CYP450 enzyme.	Impetigo [1B72]	[64]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Amiodarone caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[65]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Amiodarone caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[22]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Amiodarone caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[66]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of Amiodarone caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[67]
Quazepam	DMY4D87	Minor	Additive CNS depression effects by the combination of Amiodarone and Quazepam.	Insomnia [7A00-7A0Z]	[68]
Estazolam	DMZGXUM	Minor	Additive CNS depression effects by the combination of Amiodarone and Estazolam.	Insomnia [7A00-7A0Z]	[68]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[69]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Phenolphthalein.	Irritable bowel syndrome [DD91]	[23]
Remimazolam	DMLVSYX	Minor	Additive CNS depression effects by the combination of Amiodarone and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[68]
Naloxegol	DML0B41	Minor	Decreased clearance of Amiodarone due to the transporter inhibition by Naloxegol.	Large intestine motility disorder [DB32]	[70]
Pemigatinib	DM819JF	Moderate	Decreased metabolism of Amiodarone caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[24]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Crizotinib.	Lung cancer [2C25]	[23]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Amiodarone caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[71]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Ceritinib.	Lung cancer [2C25]	[23]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Amiodarone caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[72]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of Amiodarone caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[73]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Osimertinib.	Lung cancer [2C25]	[23]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Amiodarone caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[74]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Selpercatinib.	Lung cancer [2C25]	[23]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Halofantrine.	Malaria [1F40-1F45]	[75]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Hydroxychloroquine.	Malaria [1F40-1F45]	[23]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[23]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Amiodarone and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[76]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Amiodarone and Idelalisib.	Mature B-cell leukaemia [2A82]	[77]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Amiodarone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[78]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[79]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of Amiodarone caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[80]
Ibrutinib	DMHZCPO	Moderate	Decreased metabolism of Amiodarone caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[81]
Ponatinib	DMYGJQO	Moderate	Decreased metabolism of Amiodarone caused by Ponatinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[82]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Amiodarone due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[22]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Vemurafenib.	Melanoma [2C30]	[23]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Amiodarone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[24]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Amiodarone caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[83]
Flibanserin	DM70DTN	Moderate	Decreased metabolism of Amiodarone caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[84]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Panobinostat.	Multiple myeloma [2A83]	[23]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Siponimod.	Multiple sclerosis [8A40]	[22]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Ozanimod.	Multiple sclerosis [8A40]	[23]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Romidepsin.	Mycosis fungoides [2B01]	[23]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Amiodarone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[24]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Nilotinib.	Myeloproliferative neoplasm [2A20]	[23]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Amiodarone caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[24]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Dasatinib.	Myeloproliferative neoplasm [2A20]	[23]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Entrectinib.	Non-small cell lung cancer [2C25]	[23]
Polythiazide	DMCH80F	Major	Increased risk of ventricular arrhythmias by the combination of Amiodarone and Polythiazide.	Oedema [MG29]	[38]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Levomethadyl Acetate.	Opioid use disorder [6C43]	[24]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Lofexidine.	Opioid use disorder [6C43]	[23]
S-297995	DM26IH8	Moderate	Decreased metabolism of Amiodarone caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[24]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Amiodarone caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[85]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Rucaparib.	Ovarian cancer [2C73]	[23]
MK-4827	DMLYGH4	Moderate	Decreased clearance of Amiodarone due to the transporter inhibition by MK-4827.	Ovarian cancer [2C73]	[86]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Triclabendazole.	Parasitic worm infestation [1F90]	[23]
Rasagiline	DM3WKQ4	Major	Decreased metabolism of Amiodarone caused by Rasagiline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[22]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Pimavanserin.	Parkinsonism [8A00]	[23]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Amiodarone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[87]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[88]
Lefamulin	DME6G97	Major	Decreased metabolism of Amiodarone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[89]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Amiodarone caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[90]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Amiodarone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[91]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Degarelix.	Prostate cancer [2C82]	[23]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Amiodarone and ABIRATERONE.	Prostate cancer [2C82]	[23]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Enzalutamide.	Prostate cancer [2C82]	[23]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Amiodarone caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[92]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Bicalutamide.	Prostate cancer [2C82]	[23]
Silodosin	DMJSBT6	Moderate	Decreased clearance of Amiodarone due to the transporter inhibition by Silodosin.	Prostate hyperplasia [GA90]	[93]
Dutasteride	DMQ4TJK	Moderate	Decreased metabolism of Amiodarone caused by Dutasteride mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[94]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Amiodarone due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[24]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Amiodarone due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[24]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Levomepromazine.	Psychotic disorder [6A20-6A25]	[23]
Riociguat	DMXBLMP	Moderate	Decreased metabolism of Amiodarone caused by Riociguat mediated inhibition of CYP450 enzyme.	Pulmonary hypertension [BB01]	[22]
Everolimus	DM8X2EH	Moderate	Decreased metabolism of Amiodarone caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[95]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Amiodarone caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[24]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Amiodarone caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[96]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Amiodarone due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Amiodarone due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Tofacitinib	DMBS370	Moderate	Decreased metabolism of Amiodarone caused by Tofacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[22]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Amiodarone due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Amiodarone due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Dexamethasone	DMMWZET	Major	Increased metabolism of Amiodarone caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[47]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Amiodarone due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Quetiapine.	Schizophrenia [6A20]	[23]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Amiodarone caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[22]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Paliperidone.	Schizophrenia [6A20]	[23]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Amisulpride.	Schizophrenia [6A20]	[23]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Asenapine.	Schizophrenia [6A20]	[23]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Amiodarone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[97]
LDE225	DMM9F25	Moderate	Decreased metabolism of Amiodarone caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[98]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Amiodarone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[24]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Amiodarone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[22]
Docetaxel	DMDI269	Major	Decreased clearance of Amiodarone due to the transporter inhibition by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[99]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Amiodarone and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[24]
Armodafinil	DMGB035	Minor	Decreased metabolism of Amiodarone caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[22]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Amiodarone and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[23]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[100]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[23]
Taxol	DMUOT9V	Moderate	Decreased metabolism of Amiodarone caused by Taxol mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[101]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Pitolisant.	Somnolence [MG42]	[23]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[23]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Amiodarone due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[102]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Amiodarone caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[24]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Amiodarone caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[24]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Lenvatinib.	Thyroid cancer [2D10]	[23]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Cabozantinib.	Thyroid cancer [2D10]	[23]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Amiodarone caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[24]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Amiodarone and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[23]
-----------


⏷ Show the Full List of 212 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Amiodarone 200 mg tablet	200 mg	Oral Tablet	Oral
Amiodarone 100 mg tablet	100 mg	Oral Tablet	Oral
Amiodarone 300 mg tablet	300 mg	Oral Tablet	Oral
Amiodarone 400 mg tablet	400 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2566).
2	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 204742.
3	ClinicalTrials.gov (NCT04351763) Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms. U.S. National Institutes of Health.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
10	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11	The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59.
12	Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-38.
13	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14	A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
15	Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):363-7.
16	Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos. 2005 May;33(5):630-6.
17	Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
18	Activation of autophagy rescues amiodarone-induced apoptosis of lung epithelial cells and pulmonary toxicity in rats. Toxicol Sci. 2013 Nov;136(1):193-204. doi: 10.1093/toxsci/kft168. Epub 2013 Aug 2.
19	A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
20	Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8. [PMID: 4043097]
21	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
22	Cerner Multum, Inc. "Australian Product Information.".
23	Canadian Pharmacists Association.
24	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
25	Fabre G, Julian B, Saint-Aubert B, Joyeux H, Berger Y "Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions." Drug Metab Dispos 21 (1993): 978-85. [PMID: 7905403]
26	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
27	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
28	Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
29	Soto J, Sacristan JA, Arellano F, Hazas J "Possible theophylline-amiodarone interaction." DICP 24 (1990): 1115. [PMID: 2275239]
30	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
31	Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
32	Nattel S, Ranger S, Talajic M, et al "Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism." Am J Med 89 (1990): 235-8. [PMID: 2382671]
33	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
34	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
35	Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
36	Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
37	Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98. [PMID: 15206999]
38	Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
39	Caraco Y, Chajek-Shaul T "The incidence and clinical significance of amiodarone and acenocoumarol interaction." Thromb Haemost 62 (1989): 906-8. [PMID: 2595664]
40	Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
41	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
42	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
43	Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
44	Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
45	Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
46	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
47	Product Information. Cordarone (amiodarone). Wyeth-Ayerst Laboratories, Philadelphia, PA.
48	Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]
49	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
50	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
51	Bajaj BP, Baig MW, Perrins EJ "Amiodarone-induced torsades de pointes: the possible facilitatory role of digoxin." Int J Cardiol 33 (1991): 335-7. [PMID: 1743800]
52	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
53	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
54	Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
55	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
56	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
57	Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
58	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
59	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
60	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
61	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
62	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
63	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
64	Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
65	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
66	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
67	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
68	Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]
69	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
70	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
71	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
72	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
73	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
74	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
75	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
76	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
77	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
78	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
79	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
80	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
81	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
82	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
83	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
84	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
85	Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
86	Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
87	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
88	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
89	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
90	Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
91	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
92	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
93	Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
94	Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
95	Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
96	Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
97	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
98	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
99	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
100	Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
101	Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
102	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".